These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1209 related articles for article (PubMed ID: 20451633)

  • 21. Proarrhythmic electrical remodelling is associated with increased beat-to-beat variability of repolarisation.
    Thomsen MB; Oros A; Schoenmakers M; van Opstal JM; Maas JN; Beekman JD; Vos MA
    Cardiovasc Res; 2007 Feb; 73(3):521-30. PubMed ID: 17196569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo rabbit model of the acquired long QT syndrome.
    Johansson M; Carlsson L
    J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):247-54. PubMed ID: 11584331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: confirming the relevance of short-term variability of repolarisation in predicting drug-induced torsades de pointes.
    Detre E; Thomsen MB; Beekman JD; Petersen KU; Vos MA
    Br J Pharmacol; 2005 Jun; 145(3):397-404. PubMed ID: 15778734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcium antagonist property of CPU228, a dofetilide derivative, contributes to its low incidence of torsades de pointes in rabbits.
    Huang ZJ; Dai DZ; Li N; Na T; Ji M; Dai Y
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):310-7. PubMed ID: 17324143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potassium and calcium current blocking properties of the novel antiarrhythmic agent H 345/52: implications for proarrhythmic potential.
    Amos GJ; Abrahamsson C; Duker G; Hondeghem L; Palmer M; Carlsson L
    Cardiovasc Res; 2001 Feb; 49(2):351-60. PubMed ID: 11164845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL; Pollard CE; Hammond TG; Valentin JP
    J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
    Said TH; Wilson LD; Jeyaraj D; Fossa AA; Rosenbaum DS
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):165-71. PubMed ID: 22561361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Noninvasive cardiac activation imaging of ventricular arrhythmias during drug-induced QT prolongation in the rabbit heart.
    Han C; Pogwizd SM; Killingsworth CR; Zhou Z; He B
    Heart Rhythm; 2013 Oct; 10(10):1509-15. PubMed ID: 23773986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.
    Guns PJ; Johnson DM; Weltens E; Lissens J
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):125-34. PubMed ID: 22516473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term variability in QT interval and ventricular arrhythmias induced by dofetilide are dependent on high-frequency autonomic oscillations.
    Champeroux P; Thireau J; Judé S; Laigot-Barbé C; Maurin A; Sola ML; Fowler JS; Richard S; Le Guennec JY
    Br J Pharmacol; 2015 Jun; 172(11):2878-91. PubMed ID: 25625756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs.
    Schneider J; Hauser R; Andreas JO; Linz K; Jahnel U
    Eur J Pharmacol; 2005 Apr; 512(1):53-60. PubMed ID: 15814090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new method to calculate the beat-to-beat instability of QT duration in drug-induced long QT in anesthetized dogs.
    van der Linde H; Van de Water A; Loots W; Van Deuren B; Lu HR; Van Ammel K; Peeters M; Gallacher DJ
    J Pharmacol Toxicol Methods; 2005; 52(1):168-77. PubMed ID: 15935709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of extracardiac alpha1-adrenoceptor stimulation in assisting dofetilide to induce torsade de pointes in rabbit hearts.
    Farkas AS; Acsai K; Tóth A; Dézsi L; Orosz S; Forster T; Csanády M; Papp JG; Varró A; Farkas A
    Eur J Pharmacol; 2006 May; 537(1-3):118-25. PubMed ID: 16618484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
    Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
    Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
    Ahmad K; Dorian P
    Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of the Na+/Ca2+ exchanger, I(Na) and I(CaL) in the genesis of dofetilide-induced torsades de pointes in isolated, AV-blocked rabbit hearts.
    Farkas AS; Makra P; Csík N; Orosz S; Shattock MJ; Fülöp F; Forster T; Csanády M; Papp JG; Varró A; Farkas A
    Br J Pharmacol; 2009 Mar; 156(6):920-32. PubMed ID: 19222480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E; Watson T; Lip GY
    Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model.
    Antoons G; Oros A; Beekman JD; Engelen MA; Houtman MJ; Belardinelli L; Stengl M; Vos MA
    J Am Coll Cardiol; 2010 Feb; 55(8):801-9. PubMed ID: 20170820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uni- or bi-ventricular hypertrophy and susceptibility to drug-induced torsades de pointes.
    Panyasing Y; Kijtawornrat A; Del Rio C; Carnes C; Hamlin RL
    J Pharmacol Toxicol Methods; 2010; 62(2):148-56. PubMed ID: 20435152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.